Peptide Education Library

Commonly reported in research: mild injection-site redness or bruising, transient dizziness, temporary appetite changes, and mild GI upset. Theoretical concerns from limited data: influence on angiogenesis (use caution with active tumors), possible interaction with blood-pressure regulation. Not studied in pregnancy, pediatrics, or long-term human use. Stop and seek medical guidance for chest pain, severe headache, or any allergic reaction.

Commonly reported: injection-site redness/bruising, mild lethargy in the first days of TB-500 use, transient head-rush or lightheadedness, and occasional GI upset. Theoretical concerns: both peptides influence angiogenesis and cell migration — use extreme caution with any history of cancer. Long-term human safety data is limited. Discontinue for persistent fatigue, unexplained swelling, allergic reaction, or chest discomfort.

Generally well tolerated in short studies. Possible: injection-site reactions, mild GI symptoms, skin flushing or itching, headache. Because KPV modulates immune activity, use caution with immunosuppressive therapy or active infection. Not studied in pregnancy or long-term use. Discontinue for rash, swelling, or breathing difficulty (possible hypersensitivity).

Topical: usually well tolerated; possible mild irritation, redness, or contact dermatitis — patch test first. Injectable: local site reactions, transient metallic taste, and (rarely) copper-related symptoms (nausea, headache) if overused. Avoid in Wilson's disease or any condition of copper overload. Not for use on broken or infected skin without supervision. Keep away from eyes.

Commonly reported: nausea (especially early doses), facial flushing, appetite suppression, spontaneous erections, and darkening of existing moles/freckles. Any new, changing, or asymmetric mole warrants dermatology review — MSH analogs can obscure early melanoma. Not recommended with a personal/family history of melanoma or many atypical nevi. Avoid in pregnancy. Take first doses in the evening to minimize nausea.

Common: nausea, vomiting, diarrhea, constipation, reflux, fatigue, and injection-site reactions — usually worst after dose escalations. Serious: pancreatitis (severe persistent abdominal pain), gallbladder disease, dehydration/kidney injury from prolonged vomiting, and hypoglycemia if combined with insulin or sulfonylureas. Boxed warning for medullary thyroid carcinoma / MEN2 in rodent studies — contraindicated with personal or family history. Avoid in pregnancy. Titrate slowly and maintain hydration and adequate protein intake.

Same class-effect profile as semaglutide, often more pronounced at higher doses: nausea, vomiting, diarrhea, constipation, decreased appetite, and injection-site reactions. Serious: pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia when stacked with insulin/sulfonylureas, and vision changes in diabetics with rapid glucose drops. Same MTC/MEN2 contraindication as other GLP-1 agonists. Avoid in pregnancy. Escalate no faster than every 4 weeks and hold or reduce dose if GI symptoms are severe.

GLP-1/GIP effects: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue. Glucagon-receptor effects add: increased heart rate, mild blood pressure elevation, and transient increases in fasting glucose or liver enzymes at higher doses. Serious: pancreatitis, gallbladder disease, dehydration/kidney injury, hypoglycemia with insulin/sulfonylureas. Same MTC/MEN2 contraindication as other incretin agonists. Avoid in pregnancy, active pancreatitis, and unstable cardiovascular disease. Investigational — long-term human safety is not yet established.

Reported side effects are uncommon and mild: injection-site reactions, drowsiness (dose in the evening), vivid dreams, mild headache. Theoretical concern: telomerase activation is a proposed mechanism for cellular longevity but is also a hallmark of many cancers — avoid with any active or prior malignancy without qualified oversight. No robust long-term human safety data. Not for use in pregnancy or pediatrics.

Very limited human safety data. Reported: injection-site reactions, mild headache, sleep changes (some report vivid dreams or lighter sleep — dose earlier in the day if this occurs). Because it acts centrally, use caution with seizure disorders, active psychiatric conditions, or CNS-active medications. Avoid in pregnancy, pediatrics, and any active malignancy.

The benzyl alcohol preservative is not appropriate for neonates ("gasp syndrome") and should be avoided in pregnancy at large volumes. Rare hypersensitivity to benzyl alcohol can cause local irritation. Keep the vial refrigerated after opening, wipe the stopper with alcohol before each draw, and discard 28 days after first puncture or sooner if cloudy, discolored, or contaminated. Do not use if the seal is compromised.